US 12,275,793 B2
Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
John M. Lincecum, Jamaica Plain, MA (US); Bingbing Jiang, Brighton, MA (US); Steven N. Perrin, Newbury, MA (US); Alan Gill, Reading, MA (US); Cynthia A. Gill, Reading, MA (US); and Fernando G. Vieira, Boston, MA (US)
Assigned to ALS THERAPY DEVELOPMENT INSTITUTE, Watertown, MA (US)
Filed by ALS Therapy Development Institute, Watertown, MA (US)
Filed on Jun. 26, 2023, as Appl. No. 18/341,202.
Application 18/341,202 is a division of application No. 17/322,486, filed on May 17, 2021, granted, now 11,692,040.
Application 17/322,486 is a division of application No. 15/931,315, filed on May 13, 2020, granted, now 11,014,990, issued on May 25, 2021.
Application 15/931,315 is a division of application No. 16/125,317, filed on Sep. 7, 2018, granted, now 10,683,356, issued on Jun. 16, 2020.
Application 16/125,317 is a division of application No. 15/667,477, filed on Aug. 2, 2017, granted, now 10,106,618, issued on Oct. 23, 2018.
Application 15/667,477 is a continuation of application No. PCT/US2016/016165, filed on Feb. 2, 2016.
Claims priority of provisional application 62/111,261, filed on Feb. 3, 2015.
Prior Publication US 2024/0043549 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2875 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01)] 11 Claims
 
1. A method for treating a subject with a CD40L associated disease or disorder comprising administering to the subject a therapeutically effective amount of an isolated antibody comprising: (a) a light chain and a heavy chain, wherein the light chain comprises a light chain variable region and the heavy chain comprises a heavy chain variable region; and (b) an Fc region consisting of the amino acid sequence of SEQ ID NO:4; wherein
(i) the light chain variable region consists of the amino acid sequence of SEQ ID NO:1; and the heavy chain variable region consists of the amino acid sequence of SEQ ID NO:2; or
(ii) the light chain variable region consists of the amino acid sequence of SEQ ID NO:1; and the heavy chain variable region consists of the amino acid sequence of SEQ ID NO:6; or
(iii) the light chain variable region consists of the amino acid sequence of SEQ ID NO:5; and the heavy chain variable region consists of the amino acid sequence of SEQ ID NO:2; or
(iv) the light chain variable region consists of the amino acid sequence of SEQ ID NO5; and the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 6;
wherein the disease or disorder is a neurodegenerative or neuromuscular disease or disorder, an inflammatory or immune disease or disorder, or an autoimmune disease.